Almirall obtains the rights to market a psoriasis cream in Europe

The Spanish company will pay in advance 15 million euros to MC2 Therapeutics, in addition to payments for milestones of sales and royalties.

Almirall facilities.

MC2 Therapeutics has awarded Almirall the marketing rights in Europe for Wynzora cream for the treatment of plaque psoriasis. The Spanish company will pay 15 million euros in advance, in addition to milestone payments and double-digit royalties on European sales.

The agreement between Almirall and MC2 Therapeutics will make Wynzora a leading topical product for the treatment of plaque psoriasis in Europe, a market that currently exceeds 25 million units in annual sales volume, Almirall explained in a statement.

The market represents a significant opportunity, as the calcipotriene and betamethasone dipropionate segment accounts for approximately 35% of the market share and annual sales exceed the 300 million dollars.

Wynzora cream is currently under review in Europe, for which two phase 3 trials have been submitted, including the head-to-head study against the active Dovobet / Daivobet Gel. The success rate was 51% for Wynzora versus 6% for the vehicle. The company expects to obtain marketing authorization this year.